Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Accumulated Expenses (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Accumulated Expenses for 4 consecutive years, with $20.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 7.78% to $20.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $20.4 million, a 7.78% increase, with the full-year FY2023 number at $27.6 million, up 12.52% from a year prior.
  • Accumulated Expenses was $20.4 million for Q3 2025 at Centessa Pharmaceuticals, up from $19.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $27.6 million in Q4 2023 to a low of $15.3 million in Q1 2023.
  • A 4-year average of $22.2 million and a median of $21.4 million in 2024 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: rose 12.52% in 2023, then increased 7.78% in 2025.
  • Centessa Pharmaceuticals' Accumulated Expenses stood at $24.5 million in 2022, then rose by 12.52% to $27.6 million in 2023, then plummeted by 31.22% to $19.0 million in 2024, then rose by 7.78% to $20.4 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Accumulated Expenses are $20.4 million (Q3 2025), $19.0 million (Q3 2024), and $21.4 million (Q2 2024).